NVS
Stock Details
NVS is Novartis AG's stock. Stock exchange NYSE (Currency USD). Average price in 50 days is 90.09$. Average daily volumn in 3 months 2M. Market cap 193.01B
Stock symbol : NVS. Exchange : NYSE. Currency : USD Lastest price : 89.49$. Total volume : 1.69M. Market state CLOSED Click reload if you want to check the lastest price on market!!!
Novartis AG (NVS)
Last Price
89.49$Change
-0.35Volume
1.69M
| Previous Close | 89.84 |
| Open | 89.34 |
| Day Range | 89.27-89.99 |
| Bid | 0.00 x 1.3k |
| Ask | 0.00 x 1k |
| Volume | 1.69M |
| Average Volume | 2M |
| Market Cap | 193.01B |
| Beta | 0.49 |
| 52 Week Range | 74.09-94.26 |
| Trailing P/E | 9.23 |
| Foward P/E | 13.75 |
| Dividend (Yield %) | 3.72% |
| Ex-Dividend Date | 2022-03-08 |
Financial Details
Organization
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form me... dicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Market Cap:
193.01BRevenue:
52.88BTotal Assets:
131.79BTotal Cash:
12.41B
News about "Novartis AG"
Could This Be Novartis' Next Blockbuster Medicine?
Source from : The Motley Fool on MSN - 1 days ago
What could these results mean for PNH patients and Novartis' future? Let's dig into the data from the clinical trial and the global PNH market to get an answer. A potentially life-changing treatment ...See details»
Novartis reorg, layoffs will have minimal impact on Mass. employees
Source from : The Business Journals - 5 days ago
Novartis AG has begun a sweeping reorganization, with layoffs expected to impact around 8,000 employees across the globe. Mass. employees could be spared the worst.See details»
Novartis to pay $245 mln to end antitrust cases over Exforge drug generics
Source from : Reuters - 1 month ago
REUTERS/Arnd Wiegmann NEW YORK, Dec 28 (Reuters) - Novartis AG (NOVN.S) said on Wednesday it will pay $245 million to end antitrust litigation accusing the Swiss drugmaker of trying to delay the ...See details»
Those who invested in Novartis (VTX:NOVN) a year ago are up 15%
Source from : Yahoo - 4 days ago
To wit, the Novartis AG (VTX:NOVN) share price is 10% higher than it was a year ago, much better than the market decline of around 11% (not including dividends) in the same period. That's a solid ...See details»
Novartis news: Drug giant to pay $245M to settle antitrust case
Source from : WRAL TechWire - 29 days ago
RESEARCH TRIANGLE PARK – Novartis AG shares closed up 76 cents to $91.60 on Thursday on news of a lawsuit settlement. The pharmaceutical company is reportedly paying $245 million to settle an ...See details»
Novartis AG
Source from : Newsweek - 25 days ago
Novartis International AG is a Swiss multinational pharmaceutical company based in Basel, Switzerland. It is one of the largest pharmaceutical companies by both market cap and sales. Source: Wikipedia ...See details»
Novartis to Pay $245 Million to Settle Exforge Generics Lawsuit
Source from : Bloomberg L.P. - 1 month ago
Novartis AG agreed to pay $245 million to settle a lawsuit alleging that it attempted to delay the launch of generic copies of its Exforge blood-pressure medicine. The settlement, if approved by a ...See details»
Novartis to Pay $245 Mln in Settlement Over Antitrust Cases
Source from : MarketWatch - 1 month ago
Novartis AG said Thursday that it would pay $245 million to end antitrust cases accusing the Swiss pharmaceutical company of anticompetitive conduct in the U.S. The settlement relates to a 2011 ...See details»
Novartis AG - ADR Shares Near 52-Week High - Market Mover
Source from : Nasdaq - 1 month ago
Trading volume this week was 7.0% higher than the 20-day average. Beta, a measure of the stock’s volatility relative to the overall market stands at 0.4. The Relative Strength Index (RSI) on the ...See details»
Novartis: Chasing Revenue Might Lose Sight Of Medicine
Source from : Seeking Alpha - 6 days ago
Novartis is undergoing major change to become a pure-play innovative medicines company. Read more to see why I’m on the sidelines on this one.See details»
Novartis To Pay $245 Mln To Settle Lawsuits Over Exforge Generics
Source from : Nasdaq - 1 month ago
(RTTNews) - Swiss drugmaker Novartis AG agreed to pay $245 million to settle an antitrust litigation for allegedly attempting to delay the launch of generic versions of its Exforge blood-pressure ...See details»
Novartis generated $40 billion in innovative medicine sales, says CEO
Source from : CNBC - 18 days ago
CNBC's Meg Tirrell sits down with Dr. Vas Narasimhan, CEO of Novartis International on drug development and future of the company. Got a confidential news tip? We want to hear from you.See details»
EMA seeks to issue guidance on liver damage from Novartis' gene therapy
Source from : Euronews - 15 days ago
The European Medicines Agency (EMA) said on Friday it plans to issue advice for physicians using Novartis AG’s Zolgensma, calling on them to monitor patients for any liver injury after treatment.See details»
Novartis Settles Antitrust Cases Related To Generic Entry For Hypertension Drug
Source from : Yahoo News - 1 month ago
Novartis AG (NYSE: NVS) will pay $245 million to end antitrust litigation accusing the company of trying to delay the U.S. launch of generic versions of its Exforge, which treats hypertension to lower ...See details»